miércoles, 11 de enero de 2017

BMS $19.5million off-label marketing

The specter of illegal marketing continues to haunt the pharmaceutical industry as Bristol-Myers Squibb agreed to a $19.5 million settlement with 42 states to resolve charges of improperly promoting an antipsychotic medicine several years ago. 

The drug maker was accused of so-called , which refers to promoting a medicine for an unapproved use. In this case, Bristol-Myers allegedly touted Abilify to children, as well as elderly patients with symptoms of dementia and Alzheimer’s disease. However, the pill was not approved by the US Food and Drug Administration for the uses for which the company was targeting those populations. (Ver)
Publicar un comentario